AGENUS INC (AGEN) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-26

Key Insights

The U.S. District Court for the District of Massachusetts granted Agenus Inc. and its executives' motion to dismiss a putative securities class action lawsuit in its entirety.
The court ruled in favor of Agenus Inc. and its executives, Garo H. Armen, Christine M. Klaskin, Steven J. O'Day, and Todd Yancey, denying the plaintiff's request for leave to amend.
This dismissal of the lawsuit against Agenus Inc. and its executives removes a legal overhang and potential financial liability, which could be viewed positively by investors.

Want the newest filings?

This analysis covers the filing from 2026-03-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-16

Agenus has completed the sale of its manufacturing operations to Zydus Pharmaceuticals for $75 million, which represents a significant divestment of assets for the company.
In connection with the asset sale, Agenus has entered into an exclusive license agreement with Zydus to develop, manufacture, and commercialize its proprietary BOT/BAL cancer immunotherapy drug product in Sri Lanka and India.
Agenus has also raised $16 million through the issuance of 2,133,333 shares of common stock to Zynext Ventures, a subsidiary of Zydus Lifesciences Limited, as part of the overall transaction.

Filed: 2026-01-14

Agenus has appointed its current Chairman and CEO, Dr. Garo Armen, as the interim Chief Financial Officer and Principal Financial Officer, indicating a need for senior leadership oversight in the finance function.
The company has also appointed Austin Charette, the current Senior Director of Financial Reporting and Compliance, as the new Principal Accounting Officer, providing continuity and experience in the accounting function.
The leadership changes do not appear to be accompanied by any new compensation arrangements or modifications to existing ones, suggesting a more transitional nature of the appointments.

Filed: 2026-01-08

Agenus Inc. has entered into an amendment and release agreement with Ligand Pharmaceuticals Incorporated, which modifies the exercise price under a previously disclosed warrant from $17.30 per share to $7.50 per share.
The amendment agreement provides for a release by Ligand of liens it has on certain of Agenus' assets in exchange for the warrant exercise price reduction.
This agreement may provide Agenus with improved financial flexibility and access to capital, which could be beneficial for the company's operations and growth.

Other reports for AGENUS INC

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.